BeiGene, Ltd. — FY2017 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2017. Although the request metadata says “2017 Q4,” this is an annual Form 10-K; quarterly figures are separately disclosed. Amounts below are U.S. dollars unless stated otherwise.
Business context and reporting period
BeiGene is a commercial-stage biopharmaceutical company focused on oncology. Its portfolio included three marketed cancer medicines licensed from Celgene for China and internally developed clinical-stage candidates, notably zanubrutinib, tislelizumab and pamiparib. The company operated in one reportable segment.
The 2017 Celgene transactions granted Celgene rights to develop and commercialize tislelizumab for solid tumors in specified territories outside Asia, while BeiGene gained China distribution rights to ABRAXANE, REVLIMID and VIDAZA and acquired Celgene’s China commercial operations. BeiGene began recording product sales in September 2017.
Financial results and liquidity
| Metric | FY2017 | FY2016 |
|---|---|---|
| Total revenue | $238.4 million | $1.1 million |
| Product revenue, net | $24.4 million | None |
| Collaboration revenue | $214.0 million | $1.1 million |
| Research and development expense | $269.0 million | $98.0 million |
| Selling, general and administrative expense | $62.6 million | $20.1 million |
| Operating loss | $98.5 million | $117.1 million |
| Net loss | $93.3 million | $119.2 million |
| Net loss per ADS | $2.23 | $3.84 |
| Cash provided by (used in) operating activities | $12.8 million | $(89.5) million |
FY2017 collaboration revenue included $211.4 million of license revenue, principally from Celgene’s $263.0 million upfront payment. Product revenue was from ABRAXANE and REVLIMID; gross product sales of $28.4 million were reduced by $4.0 million for rebates and returns. Product cost of sales was $5.0 million, implying gross profit of about $19.5 million (approximately 79.6% of net product revenue).
Q4 2017 revenue was $18.2 million, operating loss was $103.8 million and net loss was $99.3 million. Q3 2017 reported $220.2 million revenue and $117.3 million net income, largely reflecting the Celgene collaboration license revenue; quarterly results therefore varied substantially.
At year-end, cash and cash equivalents were $239.6 million and short-term investments were $597.9 million, totaling $837.5 million. Working capital was $763.5 million; total assets were $1.046 billion and total liabilities were $362.2 million. Debt comprised a $146.3 million shareholder loan and $18.4 million bank loan; the shareholder loan bears 8% interest and is due in 2023 unless converted or repaid earlier. The bank loan bears 7% interest, secured by equipment and patent rights, with principal due in 2018 and 2019. Cash and investments included $139.5 million held by the Guangzhou biologics joint venture for specified facility and R&D purposes.
Operating cash flow turned positive mainly because of Celgene upfront cash and working-capital movements, rather than recurring product economics. Investing activities used $356.3 million, including investment purchases and facility spending; financing activities provided $490.4 million. The company reported an accumulated deficit of $330.5 million. In January 2018, it raised approximately $758.0 million net from an ADS offering, not included in year-end balances.
Material changes versus the prior comparable period
- Revenue increased sharply from $1.1 million to $238.4 million, driven primarily by the Celgene license transaction and, to a lesser extent, newly commenced China product sales.
- R&D expense rose 174% to $269.0 million as pivotal trials, clinical programs and staffing expanded. SG&A increased 211% to $62.6 million, reflecting organizational growth and the acquired China commercial operation.
- Annual net loss narrowed to $93.3 million from $119.2 million, despite the major increase in operating expenses, because of collaboration revenue and $11.5 million in other income, mainly government grants and subsidies.
- Operating cash flow improved from an $89.5 million use to $12.8 million provided, chiefly due to the Celgene upfront payment and changes in payables and deferred revenue.
- Cash and short-term investments increased to $837.5 million from $368.2 million. Total liabilities increased to $362.2 million from $52.9 million, including the new shareholder loan and deferred revenue.
Outlook, commentary, risks and unusual items
- Management expected expenses to rise as it advanced pivotal trials, pursued regulatory submissions, expanded China commercialization and invested in manufacturing. It expected existing year-end cash, equivalents and short-term investments to fund at least 12 months of operations, but said additional financing would be needed to complete all planned global development and commercialization.
- Management expected 2018 product revenue to increase through expanded promotion and reimbursement efforts for ABRAXANE and REVLIMID and the launch of VIDAZA. It planned China filing submissions in 2018 for zanubrutinib in mantle cell lymphoma and tislelizumab in Hodgkin’s lymphoma, subject to trial results. These are expectations, not assurances; the filing gives no numerical revenue or earnings guidance.
- Key risks include clinical-trial failure or safety issues, lengthy and changing regulatory processes, competition, reimbursement and pricing pressure, reliance on collaborators and contract manufacturers, manufacturing scale-up and quality, intellectual-property disputes, and the possibility of further capital raises and shareholder dilution.
- China-specific exposures include regulatory reform implementation uncertainty, foreign-exchange and cash-transfer restrictions, limits on distributions from subsidiaries, and differences in intellectual-property protection. The auditor noted that its PRC audit work was not fully inspected by the PCAOB.
- Clinical safety disclosures included a treatment-related fatal acute hepatitis event in a tislelizumab HCC study and immune-related toxicities in combination studies, including autoimmune hemolysis, autoimmune encephalitis and hepatitis. Trial findings were preliminary and based on stated data cutoffs.
- Other notable items: $42.9 million of share-based compensation expense; $31.8 million of deferred government grants or incentives in other long-term liabilities; and $43.2 million of capital commitments, mainly for the Guangzhou biologics facility. Management reported effective disclosure controls and internal control over financial reporting; the auditor issued unqualified opinions. No material legal proceedings were reported.
Important facts for investors to verify
- How much of reported revenue and operating cash flow came from nonrecurring Celgene upfront consideration, and how future collaboration revenue will be recognized.
- Product-level sales, rebate and return assumptions, distributor inventory, and the pace of VIDAZA launch and reimbursement access in China.
- Latest pivotal-trial results, safety updates and regulatory filing status for zanubrutinib, tislelizumab and pamiparib; disclosed trial results are not guarantees of approval or commercial success.
- Availability and permitted use of liquidity: in particular, the restrictions on the $139.5 million held by the Guangzhou joint venture and the impact of the shareholder loan’s conversion and repayment terms.
- Execution, cost and timing of the Guangzhou manufacturing buildout and commercial-scale supply arrangements, including third-party manufacturing dependencies.
- Potential effects of dilution, share-based compensation, China cash-transfer rules, and the limitations on PCAOB inspection of the auditor’s PRC work.